SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Fully equipped labs with 75-member team set-up and made operational in <100 days
The combination will support clients in getting their end-to-end discovery and development programs delivered.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Revenue from operations up 26% to Rs. 768 crores
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
Subscribe To Our Newsletter & Stay Updated
